Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $47,600.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average price of $4.76 per share, with a total value of $47,600.00. Following the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at $11,241,834.80. This trade represents a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average price of $4.46 per share, with a total value of $44,600.00.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $4.76 on Friday. The company’s 50 day simple moving average is $4.59 and its 200 day simple moving average is $4.79. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.71 and a fifty-two week high of $6.75. The firm has a market capitalization of $277.58 million, a price-to-earnings ratio of -14.88 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. As a group, analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright lifted their price objective on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Quantinno Capital Management LP bought a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth $69,000. Zacks Investment Management bought a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth $74,000. Finally, Intech Investment Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $84,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.